PubMed Health⌕ Search

PubMed · 16562113

Delayed lactose fermentation by enterobacteriaceae.

Abstract

Goodman, R. E. (University of California, Los Angeles), and M. J. Pickett. Delayed lactose fermentation by Enterobacteriaceae. J. Bacteriol. 92:318-327. 1966.-When 171 Citrobacter freundii strains and 14 Paracolobactrum arizonae strains examined, 51 of the C. freundii strains and 13 of the P. arizonae strains were found to be delayed or negative lactose fermenters. Of the slow fermenters, 65% yielded rapidly fermenting mutants in cultures undergoing delayed fermentation. Lactose fermentation could generally be hastened by increasing lactose concentrations. Many organisms which fermented lactose slowly grew readily on a medium containing lactose as the sole carbon source. Regardless of their ability to ferment lactose, all strains of C. freundii and P. arizonae investigated could be shown to possess beta-galactosidase. Delayed fermenters failed to take up lactose from the culture medium, whereas prompt fermenters did so readily. The beta-galactosidases of 12 strains of enteric bacteria were studied in crude cell extracts with respect to specific activity, stability, and activity at varying substrate (o-nitrophenyl-beta-d-galactopyranoside) concentrations, at varying pH, and in the presence of sodium, potassium, and magnesium. The widely varying specific activities and the approximate similarity of the Michaelis constants (about 2 x 10(-4)m) suggested that the strains investigated produced differing amounts of beta-galactosidase. Moreover, qualitative differences in the enzymes provided evidence that these strains synthesized different molecular forms of beta-galactosidase. The results suggested that organisms which ferment lactose only after a prolonged delay do so because they possess multiple defects in their lactose-metabolizing machinery.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R E Goodman, M J Pickett. 1966. Delayed lactose fermentation by enterobacteriaceae.. https://doi.org/10.1128/jb.92.2.318-327.1966

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗